UK small-cap RNS · 5 Dec 2025

Every announcement of UK small & mid caps under £2bn. The ones that started or moved a situation are marked – a click opens it.

Sort: Newest · Largest companies

18:00

PureTech Health PRTC £268m
PRTC's Gallop: Positive Initial Topline AML Data
PureTech's Founded Entity Gallop Oncology Announces Positive Initial Topline Data from Phase 1b Trial of LYT-200 in Relapsed/Refractory Acute Myeloid Leukemia and High-Risk Myelodysplastic Syndrome

Project milestones ahead of expectationsoutlook positive +1.3% on the day

Moved: Report LYT-200 AML/MDS Phase 1b topline results by Q3 2025: delayed → delivered – Initial topline Phase 1b efficacy and safety data in R/R AML and high-risk MDS were announced, though about two months after the Q3 2025 target. · LYT-200 AML development: Phase 1b data maturing; Phase 2 planning → Phase 1b topline reported; Phase 2 planned
07:10

Pennpetro Energy PPP £11m
HY Results for six months ended 30 September 2024 Results
Late interim results for the six months to September 2024 show a US$733,697 operating loss. The shares stay suspended and the planned Texas deal with Globalvision collapsed after the missed audit deadline.

Balance-sheet stress / refinancing outlook mixedfirst since Oct 2023 +0.0% on the day

Moved: Reorganisation under RMD Group: New CEO appointed; shares not trading → Shares suspended; 2023/24 accounts approved; 2024/25 pending · Limnytskyi License opportunity: Already announced; brought by RMD → Initial Ukrainian license; US and Canada diligence added · new: Suspension, going concern and pledged shares – Shares suspended since 1 August 2024
07:00

Neo Energy Metals NEO £15m
Appointment of New CFO and Finance Director Board change
Adds a South Africa-based CFO and Executive Director with mining M&A, funding and uranium experience, filling a gap as the company builds a team for the Beisa restart and acquisitions.

Project milestones first in 6 months +0.0% on the day

Moved: Beisa Mine restart: Implementation assessment under way → Implementation assessment; new CFO to help build team
07:00

SkinBioTherapeutics SBTX £15m
Final Results Results
Revenue up 284% to £4.6m and operating loss cut 61%, but Dermatonics and BTS came in slightly below expectations on stocking timing and order timing; FY26 guidance is held in line.

New CEO / reset £4.6m · 31% of mcapbelow expectationsoutlook positivefirst since Oct 2023 −9.0% on the day

Moved: new: Superdrug AxisBiotix roll-out – Two lines launched in >180 stores · new: Zenakine royalty ramp-up – Launched April 2025; first royalty recognised · new: Board and management changes – Appointments agreed, due diligence pending